The identification of the first potent and selective small-molecule MDM2 antagonists, the Nutlins, made it possible to perform in vivo validation studies and strengthen the notion that targeting the p53–MDM2 interaction can provide a potentially viable strategy for treating cancer. Here, MDM2 is linked to cancer.